Nkgen Biotech Inc (NKGN)
$0.77
Performance
- $0.75$0.82$0.77
2.3%
Downside
Day's Volatility :8.02%
Upside
5.86%
- $0.73$6.70$0.77
5.19%
Downside
52 Weeks Volatility :89.1%
Upside
88.51%
Returns
| Period | Nkgen Biotech Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -34.05% | 0.0% |
6 Months | -55.81% | 0.0% |
1 Year | -84.75% | 0.0% |
3 Years | -84.75% | -21.1% |
Highlights
Market Capitalization | 20.1M |
Book Value | - $2.46 |
Earnings Per Share (EPS) | -3.57 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -102.11% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 59.0K |
EBITDA | -29.4M |
Diluted Eps TTM | -3.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Nkgen Biotech Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nkgen Biotech Inc | -7.87% | -55.81% | -84.75% | -84.75% | -84.75% |
 Regeneron Pharmaceuticals, Inc. | 0.53% | 20.61% | 40.93% | 82.08% | 313.49% |
 Novo Nordisk A/s | 2.31% | 2.37% | 41.89% | 174.22% | 452.16% |
 Alnylam Pharmaceuticals, Inc. | -2.2% | 76.34% | 35.57% | 40.87% | 212.74% |
 Vertex Pharmaceuticals Incorporated | 2.37% | 15.84% | 38.0% | 150.97% | 173.61% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nkgen Biotech Inc | NA | NA | NA | 0.0 | 0.0 | -1.02 | NA | -2.46 |
Regeneron Pharmaceuticals, Inc. | 30.21 | 30.21 | 1.55 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 45.38 | 45.38 | 2.06 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nkgen Biotech Inc | NA | $20.1M | -84.75% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $125.3B | 313.49% | 30.21 | 32.04% |
Novo Nordisk A/s | Buy | $576.2B | 452.16% | 45.38 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $33.6B | 212.74% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $123.5B | 173.61% | 32.84 | -4.74% |
Insights on Nkgen Biotech Inc
Increasing Net Profit
Netprofit is up for the last 2 quarters, -33.60M → -5.38M (in $), with an average increase of 524.4% per quarter
Company Information
graf industrial corp is a blank check company. the company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. it intends to focus on industrial companies. it focuses on diversified industrial manufacturing, technology, distribution and service businesses, in the united states and canada.
Organization | Nkgen Biotech Inc |
Employees | 63 |
CEO | Dr. Paul Y. Song M.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$0.77
-11.14%
Keyarch Acquisition Corp
$0.77
-11.14%
Connexa Sports Technologies Inc
$0.77
-11.14%
Us Value Etf
$0.77
-11.14%
First Wave Biopharma Inc
$0.77
-11.14%
Global X Msci Next Emerging
$0.77
-11.14%
Fat Projects Acquisition Corp
$0.77
-11.14%
Capital Link Global Fintech
$0.77
-11.14%
Applied Uv Inc
$0.77
-11.14%